(0.07%) 5 473.12 points
(0.09%) 39 147 points
(0.38%) 17 785 points
(0.09%) $80.90
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.23%) $28.94
(3.64%) $1 022.30
(0.27%) $0.936
(0.69%) $10.68
(0.42%) $0.792
(-0.28%) $87.24
Live Chart Being Loaded With Signals
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases...
Stats | |
---|---|
今日成交量 | 8.56M |
平均成交量 | 0 |
市值 | 0.00 |
EPS | $-0.340 ( Q2 | 2022-08-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0300 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0750 (106.99%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-19 | Van Den Broek Richard | Buy | 3 750 | Common Stock |
2023-05-19 | Van Den Broek Richard | Sell | 3 750 | Restricted Stock Units |
2023-05-19 | Thorp Clay | Buy | 3 750 | Common Stock |
2023-05-19 | Thorp Clay | Buy | 3 750 | Restricted Stock Units |
2023-05-19 | Humphries William D. | Buy | 2 538 | Common Stock |
INSIDER POWER |
---|
-91.57 |
Last 98 transactions |
Buy: 2 306 852 | Sell: 1 915 751 |
音量 相关性
PhaseBio Pharmaceuticals, 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
PhaseBio Pharmaceuticals, 相关性 - 货币/商品
PhaseBio Pharmaceuticals, 财务报表
Annual | 2021 |
营收: | $10 831.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2021 |
营收: | $10 831.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2020 |
营收: | $320 000 |
毛利润: | $320.00 (0.10 %) |
EPS: | $-3.39 |
FY | 2019 |
营收: | $2.36M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.430 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PhaseBio Pharmaceuticals,
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。